You don't hand over the recipe
When an inventor brings a breakthrough to a large partner, the hard part isn't showing that the science works. It's showing enough to earn a real offer without giving away the thing that makes the science worth owning.
The discipline is staged disclosure. Before any agreement, a partner sees the thesis and the shape of the opportunity, nothing more. Under an NDA, they see enough to value the asset: the data, the mechanism, the scope of the intellectual property. The enabling know-how, the actual recipe, moves last and least, only after a signed deal, and even then through a controlled transfer. Patient data stays in a clean room. The crown-jewel ownership questions go counsel to counsel.
And when it's a competitive process rather than a single bilateral talk, the inventor sets the pace. Deeper access is earned as a partner gets serious, which is exactly what protects the leverage.
The line worth keeping: they get to see it, but only what they need, only after they're contractually bound, and only in the order and depth you choose.
Have a program worth de-risking?
See how we work with inventors →Filling a pipeline gap?
Talk to us →